B Cell News and Research

RSS

Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma

Allos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Company's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.

17 Jun 2011

Innovative adult stem cell approach could help eliminate obesity

Innovative adult stem cell research by scientists at The University of Texas Health Science Center at Houston could aid efforts to apply the brakes to stem cells that produce the type of fat ringing the waists of millions. Research appeared today online ahead of the print issue of Cell Stem Cell.

17 Jun 2011

Self-perception of body traced to specialized multisensory neurons

By taking advantage of a "body swap" illusion, researchers have captured the brain regions involved in one of the most fundamental aspects of self-awareness: how we recognize our bodies as our own, distinct from others and from the outside world. That self-perception is traced to specialized multisensory neurons in various parts of the brain that integrate different sensory inputs across all body parts into a unified view of the body.

17 Jun 2011

Roche RTCA HT Instrument allows fully-automated impedance screens for GPCRs

Label-free technologies have entered the stage of cellular drug discovery and high-throughput screening (HTS). For the measurement of G protein-coupled receptor (GPCR) activation electrical impedance represents an excellent universal readout technology, since different signaling pathways can be measured in one assay format using recombinant as well as primary cells.

17 Jun 2011

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Celgene International Sàrl announced that clinical data from two studies evaluating the use of REVLIMID® (lenalidomide) with standard R-CHOP chemotherapy in patients with untreated diffuse large B cell (DLBCL) or grade 3 follicular lymphoma were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

17 Jun 2011

Nuvilex describes advantages of cell encapsulation technology for multiple cancer therapies

Nuvilex, Inc. described today potential advantages of cell encapsulation technology for use in cancer therapies when more than one cancer-fighting drug is used.

17 Jun 2011

Wireless intelligent sensor platform for emergency responders

When Hansel and Gretel ventured into the forest, they left a trail of breadcrumbs to find their way home. In today's world, cellular phones, Global Positioning System (GPS), WiFi, and Bluetooth are the digital signals that connect us to friends, family, and colleagues while helping us find our location and map our routes.

17 Jun 2011

CTI announces positive results from Phase I-II pixantrone combination study against INHL

Cell Therapeutics, Inc. announced the publication of results posted in the online journal of Cancer of a Phase I-II study that evaluated the safety and efficacy of pixantrone when used in combination with fludarabine, dexamethasone and rituximab replacing mitoxantrone in the standard FND-R regimen with FPD-R among 28 patients with relapsed or refractory indolent non-Hodgkin's lymphoma.

17 Jun 2011

Functional vision restored after 55 years

After being hit in the eye by a stone, a detached retina left a man blind in his right eye. Despite surgery to remove a cataract when the man was 23, which temporarily restored light perception, the patient was completely blind in that eye.

17 Jun 2011

Scientists uncover how immune system responds to invading anthrax bacteria

Scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have uncovered how the body's immune system launches its survival response to the notorious and deadly bacterium anthrax.

17 Jun 2011

Tips for parents to protect teens from summer injuries

Summer is the season of backyard barbecues, scenic drives through the countryside and heat-easing dips in the pool. For all of its fun, though, summer is also the time when you're most likely to suffer an injury, especially if you're a teenager, said trauma surgeon Dr. Thomas Esposito of Loyola University Health System in Maywood, Ill.

17 Jun 2011

Key to remove stem cells responsible for fat expansion

Researchers may have found the key to developing a method to rid the body of stem cells responsible for driving fat expansion. According to a report in the June 16 Cell Stem Cell, a Cell Press publication, they've landed the first protein marker on the surface of those so-called adipose stromal cells (ASCs), which serve as progenitors of the cells that make up fat tissue.

17 Jun 2011

New weapon in the fight against cancer

A cancer diagnosis is not necessarily a death sentence. There are now quite a number of possibilities to treat cancer. In addition to radiotherapy and chemotherapy, so-called radionuclide treatment has also become an important component in the fight against the mutated cells. It involves injecting radioactive elements, so-called nuclides, into the patient's circulatory system.

17 Jun 2011

Cedars-Sinai receives National Eye Institute grant to develop gene therapy for corneal disease

Cedars-Sinai stem cell researchers investigating ways to prevent eye problems in diabetic patients have been awarded a $3 million grant from the National Eye Institute to develop gene therapy in corneal stem cells to alleviate damage to corneas that can cause vision loss.

17 Jun 2011

New Australian drug shows positive response in patients with multiple myeloma blood cancer

Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today announced it would double patient recruitment in its Phase II trial for a breakthrough antibody treatment for terminal blood cancer.

16 Jun 2011

CEVEC and Catalent Pharma Solutions offer joint cell line development service

CEVEC Pharmaceuticals, the German developer of a novel, market leading human protein expression system derived from amniocytes, and Catalent Pharma Solutions, a leading global drug development and delivery solutions provider, announced today a joint commercial cell line development service for pharma and biotech customers worldwide. The offering combines the benefits of CEVEC’s human cell line, CAP-Technology, with Catalent’s unique GPEx® (Gene Product Expression) Technology to generate high expressing stable human cell lines in a much shorter timeframe than traditional methods.

16 Jun 2011

Hopkins research suggests that blood vessels and support cells may be real targets of treatment for diabetic nerve damage

Blood vessels and supporting cells appear to be pivotal partners in repairing nerves ravaged by diabetic neuropathy, and nurturing their partnership with nerve cells might make the difference between success and failure in experimental efforts to regrow damaged nerves, Johns Hopkins researchers report in a new study.

16 Jun 2011

B Cell News and Research

Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma

Innovative adult stem cell approach could help eliminate obesity

Self-perception of body traced to specialized multisensory neurons

Roche RTCA HT Instrument allows fully-automated impedance screens for GPCRs

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Nuvilex describes advantages of cell encapsulation technology for multiple cancer therapies

Wireless intelligent sensor platform for emergency responders

CTI announces positive results from Phase I-II pixantrone combination study against INHL

Functional vision restored after 55 years

Scientists uncover how immune system responds to invading anthrax bacteria

Tips for parents to protect teens from summer injuries

Key to remove stem cells responsible for fat expansion

New weapon in the fight against cancer

Cedars-Sinai receives National Eye Institute grant to develop gene therapy for corneal disease

New Australian drug shows positive response in patients with multiple myeloma blood cancer

CEVEC and Catalent Pharma Solutions offer joint cell line development service

Hopkins research suggests that blood vessels and support cells may be real targets of treatment for diabetic nerve damage

Adaptimmune melanoma trial opening

Researchers reveal why anti-androgen therapy may fail in men with prostate cancer

Positive results from BiondVax Multimeric-001 Phase IIa trial against influenza

Immunology eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News